CytoMed Therapeutics Ltd
Research CytoMed Therapeutics Ltd (GDTC) on Bullrun: market cap USD 10.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGDTC
- ExchangeNASDAQ
- CountrySingapore
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.53M
- Financial periodFY2025
- RevenueSGD 324.39K
- Revenue growth366.7%
- Net income-SGD 3.98M
- Free cash flow-SGD 4.40M
- Gross margin79.0%
Valuation Snapshot
latest market cap is USD 10.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SGD 324.39K | -SGD 3.98M | -SGD 4.40M | 79.0% | -0.34 | SGD 2.10M | SGD 482.56K | SGD 6.54M |
| FY2024 | SGD 69.50K | -SGD 2.52M | -SGD 4.20M | 75.4% | -0.22 | SGD 4.97M | SGD 463.25K | SGD 8.97M |
| FY2023 | SGD 0 | -SGD 4.13M | -SGD 3.59M | n/a | -0.39 | SGD 9.00M | SGD 448.02K | SGD 11.25M |
| FY2022 | SGD 0 | -SGD 3.13M | -SGD 1.87M | n/a | -0.29 | SGD 1.58M | SGD 4.22M | SGD 586.98K |
| FY2021 | SGD 0 | -SGD 2.05M | -SGD 2.30M | n/a | -0.19 | SGD 2.51M | SGD 3.26M | SGD 2.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 56.49M | n/a | n/a | n/a |
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CytoMed Therapeutics Ltd's market cap?
CytoMed Therapeutics Ltd's market capitalization is USD 10.53M.
What does CytoMed Therapeutics Ltd do?
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.